Related Experiment Videos
Drug-sensitivity testing in patients with human oesophageal squamous cell carcinoma
M Terashima1, K Ikeda, C Maesawa
1First Department of Surgery, School of Medicine, Iwate Medical University, Japan.
Abstract:
To evaluate the response to chemotherapeutic agents against human oesophageal cancer, 19 samples were tested by the human tumour clonogenic assay (HTCA), 21 samples by subrenal capsule assay (SRCA) and 33 samples by SRCA with immunosuppressant (IS-SRCA). The evaluability rate of was 21% for HTCA, 95% for SRCA and 91% for IS-SRCA. No active agent was detected by HTCA, however, 29% of the drugs tested by SRCA and 22% by IS-SRCA were considered to be active. Histological analysis revealed substantial inflammatory infiltrates and poor tumour cell preservation with SRCA; however, infiltrates were minimal and there was a high degree of tumour cell preservation with IS-SRCA. The response rates of IS-SRCA were comparable with those of prior clinical tests for each drug. These results suggested that IS-SRCA is the most useful drug sensitivity test for human oesophageal cancer.
Insights
The immunosuppressant subrenal capsule assay (IS-SRCA) shows higher drug activity detection for esophageal cancer than other methods. IS-SRCA offers better tumor cell preservation and evaluability for chemotherapy sensitivity testing.
Area of Science:
- Oncology
- Pharmacology
- Experimental Medicine
Background:
- Esophageal cancer presents challenges in predicting chemotherapy response.
- Accurate drug sensitivity testing is crucial for effective treatment selection.
Purpose of the Study:
- To compare the efficacy of three assays in evaluating chemotherapeutic agent response in human esophageal cancer.
- To identify the most reliable assay for predicting drug sensitivity.
Main Methods:
- Human tumor clonogenic assay (HTCA), subrenal capsule assay (SRCA), and immunosuppressant subrenal capsule assay (IS-SRCA) were employed.
- Evaluability rates, drug activity detection, and histological characteristics were assessed for each assay.
- IS-SRCA demonstrated high evaluability (91%) and tumor cell preservation.
Main Results:
- HTCA showed low evaluability (21%) and detected no active agents.
- SRCA had high evaluability (95%) but showed poor tumor cell preservation.
- IS-SRCA identified active agents in 22% of cases with minimal inflammation and good tumor cell preservation, comparable to clinical data.
Conclusions:
- The immunosuppressant subrenal capsule assay (IS-SRCA) is a superior method for evaluating drug sensitivity in human esophageal cancer.
- IS-SRCA provides a more accurate and reliable prediction of chemotherapy response compared to HTCA and SRCA.